DSM XD high cell density process technology granted patents in several countries

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V. (NYSE, Euronext: DSM KON), announced today that several countries have granted patents or have given statements of patent allowance to its proprietary XD® high cell density process technology.

DSM Biologics focuses on optimizing biopharmaceutical manufacturing through its unique set of technologies. The XD® technology is an important building block in DSM's vision for the future of biopharmaceutical manufacturing. This technology is a highly intensified cell culture process with titer achievement 5-to-15 times higher compared to current standard biomanufacturing processes.  It is widely applicable for multiple products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems. XD® has also shown impressive results for biosimilars and ethical drugs with respect to both volume and product quality.

Karen King, President of DSM Biologics, commented, "Reviews at patent offices across the globe recognized the patentability of DSM's XD® process, amongst others the US and the Eurasian Patent Offices where patents have been granted. Other countries such as South Korea and Australia have provided allowance letters. This is another milestone for DSM Biologics' technology portfolio which can significantly reduce cost, scale-up risk and capital risk of biopharmaceutical manufacturing. The XD® technology offers the opportunity to meet commercial annual demands of 500 kilograms of biopharmaceuticals in a smaller manufacturing footprint than traditional methods. These flexible and cost effective facilities can be easily installed across the globe."

DSM is making the XD® technology available in combination with their contract manufacturing services, and also for license. Licensing includes customer support to set-up the XD® process in-house. The XD® technology is complemented by DSM's proprietary capture and clarification technology called RHOBUST®. Together these technologies significantly optimize the cost and risk profile of current mammalian production processes.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers reveal cellular foundations of functional brain networks in humans